• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    11/13/24 8:32:26 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VINC alert in real time by email
    SC 13G/A 1 d892826dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    VINCERX PHARMA, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    92731L106

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

    Taylor H. Wilson, Esq.

    Haynes and Boone, LLP

    2801 N Harwood St, Suite 2300

    Dallas, Texas 75201

    (214) 651-5000

     

     

     


    SCHEDULE 13G

     

    CUSIP No. 92731L106

     

     1   

     Names of reporting persons

     

     Prosight Management, LP

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with:

       5    

     Sole voting power

     

     0

       6   

     Shared voting power

     

     1,678,635

       7   

     Sole dispositive power

     

     0

       8   

     Shared dispositive power

     

     1,678,635

     9   

     Aggregate amount beneficially owned by each reporting person

     

     1,678,635

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     5.0% (1)

    12  

     Type of reporting person (see instructions)

     

     IA

     

    (1)

    Based upon 33,555,903 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the U.S. Securities and Exchange Commission (the “SEC”) on November 12, 2024.


    SCHEDULE 13G

     

    CUSIP No. 92731L106

     

     1   

     Names of reporting persons

     

     Prosight Fund, LP

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with:

       5    

     Sole voting power

     

     0

       6   

     Shared voting power

     

     127,477

       7   

     Sole dispositive power

     

     0

       8   

     Shared dispositive power

     

     127,477

     9   

     Aggregate amount beneficially owned by each reporting person

     

     127,477

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     0.4% (1)

    12  

     Type of reporting person (see instructions)

     

     PN

     

    (1)

    Based upon 33,555,903 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 12, 2024.


    SCHEDULE 13G

     

    CUSIP No. 92731L106

     

     1   

     Names of reporting persons

     

     Prosight Plus Fund, LP

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with:

       5    

     Sole voting power

     

     0

       6   

     Shared voting power

     

     420,781

       7   

     Sole dispositive power

     

     0

       8   

     Shared dispositive power

     

     420,781

     9   

     Aggregate amount beneficially owned by each reporting person

     

     420,781

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     1.3% (1)

    12  

     Type of reporting person (see instructions)

     

     PN

     

    (1)

    Based upon 33,555,903 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 12, 2024.


    SCHEDULE 13G

     

    CUSIP No. 92731L106

     

     1   

     Names of reporting persons

     

     Prosight Partners, LLC

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with:

       5    

     Sole voting power

     

     0

       6   

     Shared voting power

     

     1,678,635

       7   

     Sole dispositive power

     

     0

       8   

     Shared dispositive power

     

     1,678,635

     9   

     Aggregate amount beneficially owned by each reporting person

     

     1,678,635

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     5.0% (1)

    12  

     Type of reporting person (see instructions)

     

     OO

     

    (1)

    Based upon 33,555,903 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 12, 2024.


    SCHEDULE 13G

     

    CUSIP No. 92731L106

     

     1   

     Names of reporting persons

     

     W. Lawrence Hawkins

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

     United States of America

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with:

       5    

     Sole voting power

     

     0

       6   

     Shared voting power

     

     1,678,635

       7   

     Sole dispositive power

     

     0

       8   

     Shared dispositive power

     

     1,678,635

     9   

     Aggregate amount beneficially owned by each reporting person

     

     1,678,635

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     5.0% (1)

    12  

     Type of reporting person (see instructions)

     

     IN, HC

     

    (1)

    Based upon 33,555,903 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 12, 2024.


    Item 1.

     

    (a)

    Name of issuer:

    Vincerx Pharma, Inc. (the “Issuer”)

     

    (b)

    Address of issuer’s principal executive offices:

    260 Sheridan Avenue, Suite 400

    Palo Alto, California 94306

     

    Item 2.

     

    (a)

    Name of person filing:

    This statement is jointly filed by and on behalf of each of Prosight Management, LP, a Delaware limited partnership (“Prosight Management”), Prosight Fund, LP, a Delaware limited partnership (“Prosight Fund”), Prosight Plus Fund, LP, a Delaware limited partnership (“Prosight Plus Fund”), Prosight Partners, LLC, a Delaware limited liability company (“Prosight Partners”), and W. Lawrence Hawkins (collectively referred herein as “Reporting Persons”). Prosight Management is the general partner and investment manager of, and may be deemed to indirectly beneficially own securities owned by, Prosight Fund and Prosight Plus Fund. Prosight Management is a sub-advisor for certain separate managed accounts (collectively, the “Managed Accounts”) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Prosight Partners is the general partner of, and may be deemed to beneficially own, securities beneficially owned by Prosight Management. Mr. Hawkins is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, Prosight Partners. Prosight Fund, Prosight Plus Fund, and the Managed Accounts are the record and direct beneficial owner of the shares of Common Stock of the Issuer covered by this statement. Prosight Fund disclaims beneficial ownership of the shares of Common Stock of the Issuer held by each of the Managed Accounts and Prosight Plus Fund. Prosight Plus Fund disclaims beneficial ownership of the shares of Common Stock of the Issuer held by each of the Managed Accounts and Prosight Fund.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

     

    (b)

    Address of principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Prosight Management, LP, 5956 Sherry Lane, Suite 1365, Dallas, Texas 75225.


    (c)

    Citizenship:

    See Item 4 on the cover page(s) hereto.

     

    (d)

    Title of class of securities:

    Common Stock, $0.0001 par value per share (“Common Stock”)

     

    (e)

    CUSIP No.:

    92731L106

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
      (e)    ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:______

     

    Item 4.

    Ownership.

     

    (a)

    Amount beneficially owned: See Item 9 on the cover pages(s) hereto.

     

    (b)

    Percent of class: See Item 11 on the cover page(s) hereto.

     

    (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     

    PROSIGHT MANAGEMENT, LP
    By:   Prosight Partners, LLC
    Its:   General Partner
    By:   /s/ W. Lawrence Hawkins
    Name:   W. Lawrence Hawkins
    Title:   Sole Manager
    PROSIGHT FUND, LP
    By:   Prosight Management, LP
    Its:   General Partner
    By:   Prosight Partners, LLC
    Its:   General Partner
    By:   /s/ W. Lawrence Hawkins
    Name:   W. Lawrence Hawkins
    Title:   Sole Manager
    PROSIGHT PLUS FUND, LP
    By:   Prosight Management, LP
    Its:   General Partner
    By:   Prosight Partners, LLC
    Its:   General Partner
    By:   /s/ W. Lawrence Hawkins
    Name:   W. Lawrence Hawkins
    Title:   Sole Manager
    PROSIGHT PARTNERS, LLC
    By:   /s/ W. Lawrence Hawkins
    Name:   W. Lawrence Hawkins
    Title:   Sole Manager
    W. LAWRENCE HAWKINS
    /s/ W. Lawrence Hawkins


    EXHIBIT INDEX

     

    Exhibit

      

    Description of Exhibit

    99.1    Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on May 3, 2024, by the Reporting Persons with the SEC).
    Get the next $VINC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VINC

    DatePrice TargetRatingAnalyst
    1/14/2022$25.00Buy
    HC Wainwright & Co.
    12/23/2021$25.00Overweight
    Cantor Fitzgerald
    11/1/2021$24.00Outperform
    SVB Leerink
    9/13/2021$30.00Buy
    Laidlaw
    8/25/2021$26.00Buy
    B. Riley Securities
    8/13/2021$33.00 → $30.00Buy
    Chardan Capital
    More analyst ratings

    $VINC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

      Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 SAN MATEO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission ("SEC") on or about April 28, 2025, which will remove Vincerx's common stock from listing and registration on The Nasdaq Stock Market ("Nasdaq"). On April 14, 2025, Vincerx received written notice from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because

      4/17/25 4:45:00 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

      SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. Following this decision, the Company's board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities. "I want to express our deepest gratitude to the investigators, patients, employees, and partners who have supported Vincerx's mission," said Raquel Izumi, Ph.D., Acting Chief Executive Officer of Vincerx. "Your co

      4/8/25 4:05:00 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

      SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has entered into a non-binding letter of intent ("LOI") with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx. Under the proposed terms, a subsidiary of Vincerx would merge into QumulusAI, with QumulusAI stockholders receiving shares of Vincerx common stock.

      3/18/25 8:52:56 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Haas Kevin claimed ownership of 42,776 shares (SEC Form 3)

      3 - Vincerx Pharma, Inc. (0001796129) (Issuer)

      1/6/25 4:29:47 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Thomas Tom C

      4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

      8/14/24 8:11:28 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Hamdy Ahmed Md

      4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

      8/14/24 8:07:30 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    SEC Filings

    See more
    • SEC Form EFFECT filed by Vincerx Pharma Inc.

      EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)

      5/5/25 12:15:04 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Vincerx Pharma Inc.

      EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)

      5/5/25 12:15:05 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Vincerx Pharma Inc.

      EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)

      5/5/25 12:15:15 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Vincerx Pharma Inc.

      SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

      11/14/24 3:39:40 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

      SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

      11/14/24 11:57:03 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

      SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

      11/13/24 8:32:26 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Vincerx Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00

      1/14/22 6:06:29 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Vincerx Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00

      12/23/21 6:37:41 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Vincerx Pharma with a new price target

      SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00

      11/1/21 6:31:16 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care